Santarus Inc

Santarus — Investor Presentation (June 2011)

28 slides from Santarus's investor presentation, Jun 22, 2011

  1. Slide 1: Santarus

    k= wy SAVIAARLS NasdaqGS: SNTS June 22, 2011

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation may include forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management. The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its

  3. Slide 3: Santarus - Investment Rationale

    Santarus - Investment Rationale 2 differentiated commercial products for adults with type 2 diabetes - combined peak sales potential of $300M to $400M (Glumetza(r) and Cycloset(r))2 late-stage development products (budesonide MMX(r) and Rhucin(r)) with combined peak sales potential of ~$500 millionC

  4. Slide 4: Santarus Offers Attractive Mix of Commercial & Development Opportunities

    Santarus Offers Attractive Mix of Commercial & Development Opportunities Development Opportunities Development Opportunities *Zegerid(r) is a non-promoted prescription product that continues to generate revenue. In addition, Zegerid OTC(r) is promotedby Merck Consumer Care. GlaxoSmithKline and Norgi

  5. Slide 5: Specialty Focus - Leverage Commercial Investment

    Specialty Focus - Leverage Commercial Investment Sales Reps Physician Specialist Today Near Term Long Term Products & Product Candidates 110 Endocrinologists X Glumetza(r)Cycloset(r) +80 Gastroenterologists X Budesonide MMX(r)Rifamycin SV MMX(r)SAN-300 +25 Allergists/Immunologists X Rhucin(r)SAN-300

  6. Slide 6: Financial Focus - Increase Shareholder Value

    Financial Focus - Increase Shareholder Value Sales per Rep Revenue SG&A as % RevenueR&D as % Revenue Profits & Cash Flow June 22, 2011 6

  7. Slide 7: Glumetza (metformin hydrochloride extended release tablets)

    Glumetza(r) (metformin hydrochloride extended release tablets)* Once-daily, extended-release metformin 500 mg & 1000 mg tabletsIndicated for adults with type 2 diabetesAdjunct to diet and exercise to improve glycemic controlDesigned to reduce GI side effects1Q 2011 promotion revenue of $10.3 million

  8. Slide 8: Weekly Glumetza Script Performance

    Weekly Glumetza(r) Script Performance Source: IMS NPA Weekly (NGPS) 8 June 22, 2011 (CHART) Through week ending June 10, 2011

  9. Slide 9: Cycloset (bromocriptine mesylate) Tablets

    Cycloset(r) (bromocriptine mesylate) Tablets* Cycloset(r) (bromocriptine mesylate) Tablets* First and only centrally acting dopamine agonist oral antidiabeticQuick-release formulation of bromocriptine mesylateIndicated as an adjunct to diet and exercise to improve glycemic control in adults with typ

  10. Slide 10: Cycloset Prescriber and Prescription Trends

    Cycloset(r) Prescriber and Prescription Trends June 22, 2011 10 Prescriptions normalized to 120 pills per Rx Source: IMS Health, Weekly NPA and Xponent Weekly Through week ending June 10, 2011

  11. Slide 11: Cycloset Improves HbA1c When Added to Other Agents

    Cycloset(r) Improves HbA1c When Added to Other Agents HbA1c changes from baseline to week 24 0.6% to 0.9% HbA1c reductions when added to other oral antidiabetics* Efficacy data in combination with thiazolidinediones (TZDs) are limited. Efficacy has not been confirmed in combination with insulin. *Fi

  12. Slide 12: Cycloset Controls Glucose Throughout the Day

    Cycloset(r) Controls Glucose Throughout the Day 2-hour postprandial plasma glucose (PPG) levels at week 24: change vs. placebo* All PPG levels (mg/dL) were significantly lower vs placebo (p<.05)* Findings from a 24-week, placebo-controlled, monotherapy trial that evaluated the efficacy and safety of

  13. Slide 13: Cycloset Demonstrated Cardiovascular Safety Profile

    Cycloset(r) Demonstrated Cardiovascular Safety Profile Cycloset(r) Demonstrated Cardiovascular Safety Profile In a 3,070 patient, 52-week safety study, Cycloset use was not associated with an increased risk for adverse cardiovascular events 55% relative risk reduction for MACE* endpoint vs placebo.

  14. Slide 14: Attractive Late-stage Product Candidates

    Attractive Late-stage Product Candidates Budesonide MMX(r)Two Phase III studies completed for the induction of remission of mild or moderate active ulcerative colitis Extended use study completed (last patient last visit) in May 2011; top- line data in 2H 2011Plan to submit NDA by end of 2011 follow

  15. Slide 15: Selected IBD Branded Promoted Products - US TRx Growth and IMS Sales Growth

    Selected IBD Branded Promoted Products - US TRx Growth and IMS Sales GrowthMay '10 - April '11 LTM Total TRx = 3.7 million LTM Total IMS Sales = $1.9 billion (CHART) (CHART) June 22, 2011 15

  16. Slide 16: IBD Therapy - Pill Burden

    IBD Therapy - Pill Burden Asacol(r)/ Asacol(r) HD (TID) + +Entocort(r) EC (QD) Lialda(r) (QD) Pentasa(r) (QID) + + + Budesonide MMX(r)* (QD) Product Pills Per Day(induction of remission) *Budesonide MMX is an investigational product and is not FDA approved June 22, 2011 16

  17. Slide 17: Budesonide MMX Phase III Clinical Studies

    Budesonide MMX(r) Phase III Clinical Studies Over 1000 patients enrolled across four treatment arms in two Phase III clinical studies for the induction of remission in mild or moderate active ulcerative colitis12-month extension study completed (last patient last visit) in May 2011; top-line data 2H

  18. Slide 18: Budesonide MMX Positive Results in Induction of Remission of Active Ulcerative Colitis

    (CHART) (CHART) Budesonide MMX(r) 9 mg - Positive Results in Induction of Remission of Active Ulcerative Colitis U.S. Phase III Clinical Study E.U. Phase III Clinical Study 7.4% 13.2% 12.1% 4.5% 17.4%+ 8.3% 12.6%+- Placebon=121 PlaceboN=89 Bud MMX(r) 9mgn=123 Bud MMX(r) 9mgN=109 Bud MMX(r) 6mgn=121

  19. Slide 19: Budesonide MMX Generally Well Tolerated

    Budesonide MMX(r) Generally Well Tolerated Budesonide MMX(r) Generally Well Tolerated Treatment related AE data from U.S. and E.U. studies Top-line study results indicate that budesonide MMX(r) 9 mg and 6 mg were generally well tolerated and the frequency of treatment related adverse events was simi

  20. Slide 20: Extension Study with Budesonide MMX Completed May 11

    Extension Study with Budesonide MMX(r) 6 mg Completed May 2011 12-month, double-blind, placebo-controlled extended use study (extension of 8 week induction studies) with 123 patients enrolledPrimary objectivesEvaluate long-term safety and tolerability of budesonide MMX 6 mgCollect data on the effica

  21. Slide 21: Rhucin (recombinant human C1 inhibitor)

    Rhucin(r) (recombinant human C1 inhibitor) U.S. regulatory statusOrphan drug designation in U.S. for treatment of acute attacks of HAEPhase III study initiated in February with dosing regimen at 50 U/kgExpect to complete Phase III study by 3Q 2012Promoted in E.U. as Ruconest(tm) by Swedish Orphan Bi

  22. Slide 22: U.S. HAE Treatments Expected to Evolve to Acute Therapies

    U.S. HAE Treatments Expected to Evolve to Acute Therapies Cinryze(r)10-15% of patientsMost severe casesVery frequent attacksHistory of life- threatening or intense pain Significant impact on QOL Berinert(r), Kalbitor(r), Others60-70% of patientsMild/moderate casesMore frequent attacksPeripheral loca

  23. Slide 23: Rhucin - Two Placebo-Controlled Studies Completed in Treating Acute Attacks of HAE

    Rhucin(r) - Two Placebo-Controlled Studies Completed in Treating Acute Attacks of HAE Primary Endpoint (minutes) Primary Endpoint (minutes) Primary Endpoint (minutes) Primary Endpoint (minutes) Primary Endpoint (minutes) 100 U/kg N =13 50 U/kg N =12 Placebo N =13 p-values Time to the beginning of re

  24. Slide 24: Rifamycin SV MMX - Phase III Study in TD

    Rifamycin SV MMX(r) - Phase III Study in TD Broad-spectrum in vitro antibacterial activity, including C. difficile20 year history of use of rifamycin SV in Europe in IV/IM formsMMX is an oral tablet form that selectively delivers to the colon Negligible systemic absorption (<1%)Good safety & tolerab

  25. Slide 25: Early-Stage Product Candidate: SAN-300 (Anti-VLA-1 Antibody)

    Early-Stage Product Candidate: SAN-300 (Anti-VLA-1 Antibody) SAN-300 has potentially broad clinical applications in autoimmune and inflammatory diseasesEfficacy in multiple preclinical models of inflammation, such as rheumatoid arthritis, inflammatory bowel disease, psoriasis and organ transplantHum

  26. Slide 26: Historical Financial Performance 2006 - 2010

    Historical Financial Performance 2006 - 2010 Total Revenue Net Income (Loss)(CHART) 2006 2007 2009 2008 2010 $ Millions (CHART) $49 June 22, 2011 26

  27. Slide 27: 1Q 2011 and 2010 Full Year Financial Results

    3 Months Ended March 31, Cash, cash equivalents & short-term investments: $54.8 million at March 31, 2011 Notes:Generic competition for Zegerid(r) started in June 2010Fiscal 2010 expenses included $7.1 million in restructuring costs, $15 million upfront for Rhucin agreement and $5.4 million in succe

  28. Slide 28: Near Term Value Drivers for Santarus

    Near Term Value Drivers for Santarus Glumetza(r) - expect significant revenue growthCycloset(r) - educate endocrinologists and establish sales momentumBudesonide MMX(r) - NDA submission planned for end of 2011Advance clinical programsRhucin Phase III study in HAE (paid for by Pharming) Rifamycin SV

Santarus — Investor Presentation (June 2011) on 6ix